File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pregnancy outcomes, embryonic and fetal development in maternal exposure to chinese medicines

TitlePregnancy outcomes, embryonic and fetal development in maternal exposure to chinese medicines
Authors
KeywordsDevelopment
Embryotoxicity
Herbal medicines
Pregnancy
Issue Date2013
Citation
Birth Defects Research Part C - Embryo Today: Reviews, 2013, v. 99, n. 4, p. 275-291 How to Cite?
AbstractChinese medicine is a common name for a collection of Chinese Materia Medica with therapeutic properties for medical treatment and healing. Similar to Western pharmaceuticals, Chinese medicines are not free of risk, and have the potential to cause adverse pregnancy outcomes and affect embryonic and fetal development. However, most clinical data concerning safety of maternal exposure to Chinese medicines during pregnancy are not available and the conclusion remains elusive. Some individual clinical trials of Chinese medicines reported some minor adverse effects during pregnancy, whereas few animal studies identified some adverse maternal and perinatal effects, as well as embryotoxic potentials. Basic research and mechanistic studies of the teratogenicity of Chinese medicines are still lacking. There is an urgent need for testing the safety of Chinese medicines before recommendation and commercialization. Until more reliable and scientific research data become available, clinicians should consider both the risks and benefits before recommending Chinese medicines to pregnant women. More systematic investigations of the safety implications of the use of Chinese medicines are highly recommended, in addition to more clinical trials with a larger sample size to confirm its safety during pregnancy. This review includes a critical overview of available clinical and experimental data and provides directions to study the safety issue of Chinese medicines for pregnancy. © 2013 Wiley Periodicals, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/343142
ISSN
2018 Impact Factor: 3.200
2019 SCImago Journal Rankings: 1.073

 

DC FieldValueLanguage
dc.contributor.authorWang, Chi Chiu-
dc.contributor.authorLi, Lu-
dc.contributor.authorSan Lau, Clara Bik-
dc.contributor.authorLeung, Ping Chung-
dc.contributor.authorFung, Kwok Pui-
dc.date.accessioned2024-05-10T09:05:47Z-
dc.date.available2024-05-10T09:05:47Z-
dc.date.issued2013-
dc.identifier.citationBirth Defects Research Part C - Embryo Today: Reviews, 2013, v. 99, n. 4, p. 275-291-
dc.identifier.issn1542-975X-
dc.identifier.urihttp://hdl.handle.net/10722/343142-
dc.description.abstractChinese medicine is a common name for a collection of Chinese Materia Medica with therapeutic properties for medical treatment and healing. Similar to Western pharmaceuticals, Chinese medicines are not free of risk, and have the potential to cause adverse pregnancy outcomes and affect embryonic and fetal development. However, most clinical data concerning safety of maternal exposure to Chinese medicines during pregnancy are not available and the conclusion remains elusive. Some individual clinical trials of Chinese medicines reported some minor adverse effects during pregnancy, whereas few animal studies identified some adverse maternal and perinatal effects, as well as embryotoxic potentials. Basic research and mechanistic studies of the teratogenicity of Chinese medicines are still lacking. There is an urgent need for testing the safety of Chinese medicines before recommendation and commercialization. Until more reliable and scientific research data become available, clinicians should consider both the risks and benefits before recommending Chinese medicines to pregnant women. More systematic investigations of the safety implications of the use of Chinese medicines are highly recommended, in addition to more clinical trials with a larger sample size to confirm its safety during pregnancy. This review includes a critical overview of available clinical and experimental data and provides directions to study the safety issue of Chinese medicines for pregnancy. © 2013 Wiley Periodicals, Inc.-
dc.languageeng-
dc.relation.ispartofBirth Defects Research Part C - Embryo Today: Reviews-
dc.subjectDevelopment-
dc.subjectEmbryotoxicity-
dc.subjectHerbal medicines-
dc.subjectPregnancy-
dc.titlePregnancy outcomes, embryonic and fetal development in maternal exposure to chinese medicines-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/bdrc.21050-
dc.identifier.pmid24339038-
dc.identifier.scopuseid_2-s2.0-84890360246-
dc.identifier.volume99-
dc.identifier.issue4-
dc.identifier.spage275-
dc.identifier.epage291-
dc.identifier.eissn1542-9768-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats